The Global Alliance for TB Drug Development

EU Legislative Interests

EU legislative proposal: European Health Emergency Preparedness and Response Authority (HERA) – meetings with European Commission officials; Horizon Europe, European and Developing Countries Clinical Trials Partnership (EDCTP), and EU initiatives connected to research and innovation (R&I) – meetings with European Commission officials; EU Global Health Strategy – meetings with European Commission officials; EU Pharmaceutical Package – contribution to consultation and meetings with European Commission officials.

Communication Activities

We participated in regular meetings with HERA, EDCTP3 and European Commission officials regarding TB Alliance Research and Innovation activities, and actively engaged in communications related to ongoing Commission policies related to EDCTP3 initiatives, EU Global Health Strategy, the EU Pharmaceutical Package and the possibility for the introduction of a novel Priority Review Voucher (PRV) type mechanism to encourage R&I investments in neglected disease research. Furthermore, we highlighted the contributions of the Commission and its various initiatives to support the work of global medical R&I in the context of the "Keeping the Promise: Product Development Partnerships' Role in the New Age of Health Research and Product Development" Report that we help draft and distribute.

Interests Represented

Does not represent commercial interests

Member Of

DSW - https://www.dsw.org/en/eu/ AMR Stakeholder Network - https://epha.org/amr-stakeholder-network/

Organisation Members

- https://era4tb.org - https://www.unite4tb.org

Additional Information

TB Alliance is a consortium partner eligible to recieve funds under the IMI program UNITE4TB and the IHI- funded ITHEMYC project.